JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2006; 48:1774-1781, doi:10.1016/j.jacc.2006.06.067
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (22)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davidson, M. H.
Right arrow Articles by Revkin, J. H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Davidson, M. H.
Right arrow Articles by Revkin, J. H.
Related Collections
Right arrowRelated Article

Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density Lipoprotein Cholesterol Levels

Michael H. Davidson, MD, FACC*,*, James M. McKenney, PharmD{dagger}, Charles L. Shear, DrPH{ddagger} and James H. Revkin, MD, FACC{ddagger}

* Rush-Presbyterian-St. Luke’s Medical Center, Chicago, Illinois
{dagger} Virginia Commonwealth University, Richmond, Virginia
{ddagger} Pfizer Global Research and Development, New London, Connecticut


Figure 1
View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1 Schematic representation of study design and numbers of subjects. Sample size was calculated based on earlier torcetrapib studies, with 25 subjects per group yielding 80% power to detect a 25% treatment difference in high-density lipoprotein cholesterol (HDL-C), assuming a common standard deviation of 30.5% and 2-sided t test with 5% type I error. LOCF = last observation carried forward (i.e., subjects with baseline and at least one post-baseline HDL-C measurement); R = randomization.

 

Figure 2
View larger version (22K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2 Mean change in high-density lipoprotein cholesterol (HDL-C) over the course of the study—all subjects.

 

Figure 3
View larger version (23K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 3 Mean change in low-density lipoprotein cholesterol (LDL-C) over the course of the study—all subjects.

 

Figure 4
View larger version (22K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 4 Change in low-density/high-density lipoprotein cholesterol (LDL-C/HDL-C) ratio over the course of the study—all subjects.

 

Figure 5
View larger version (34K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 5 Least-squares mean change in systolic (A) and diastolic (B) blood pressure over the course of the study.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2006 by the American College of Cardiology Foundation.